ANIP Q2 2022 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$74M+51.9% YoY

Gross Profit

$39M52.2% margin

Operating Income

-$13M-17.5% margin

Net Income

-$15M-20.2% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

+14.5%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$13M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$751M

Total Liabilities

$414M

Stockholders' Equity

$337M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$74M	$49M	+51.9%
Gross Profit	$39M	$26M	+46.6%
Operating Income	-$13M	-$16M	+17.0%
Net Income	-$15M	-$14M	-5.8%

Revenue Segments

Generics, Established Brands, and Other

$64M86%

Rare Disease

$10M14%

Geographic Segments

United States

$73M99%

Canada

$1M1%